Cidara Therapeutics Announces Clinical Management Team Changes
“We wish Dirk all the best as he pursues his new endeavor, and we extend
our sincere gratitude for his exceptional work in spearheading our
antifungal development programs,” said
Dr. Sandison has been with Cidara since
About
Cidara is a clinical-stage biotechnology company focused on the
discovery, development and commercialization of novel anti-infectives
for the treatment of diseases that are inadequately addressed by current
standard-of-care therapies. Cidara's initial product portfolio comprises
two formulations of the company's novel echinocandin, CD101. CD101 IV is
being developed as a once-weekly, high-exposure therapy for the
treatment and prevention of serious, invasive fungal infections. CD101
topical is being developed for the treatment and prevention of
vulvovaginal candidiasis (VVC), a prevalent mucosal infection. In
addition, Cidara has developed a proprietary immunotherapy platform,
Cloudbreak™, designed to create compounds that direct a patient's immune
cells to attack and eliminate pathogens that cause infectious disease.
Cidara is headquartered in
Forward-Looking Statements
Statements contained in this press release regarding matters that are
not historical facts are "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements regarding Cidara’s clinical management change and Dr.
Sandison’s ability to effectively replace Dr. Thye. Risks that
contribute to the uncertain nature of the forward-looking statements
include: the success and timing of Cidara’s preclinical studies and
clinical trials; regulatory developments in
View source version on businesswire.com: http://www.businesswire.com/news/home/20160901005355/en/
Source:
INVESTOR CONTACT:
Westwicke Partners, LLC
Robert H.
Uhl, 858-356-5932
Managing Director
robert.uhl@westwicke.com
or
MEDIA
CONTACT:
Sam Brown Inc.
Mike Beyer, 312-961-2502
mikebeyer@sambrown.com